Head-To-Head Survey: XOMA (NASDAQ:XOMAP) versus Benitec Biopharma (NASDAQ:BNTC)

XOMA (NASDAQ:XOMAP) and Benitec Biopharma (NASDAQ:BNTC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Insider and Institutional Ownership

52.2% of Benitec Biopharma shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares XOMA and Benitec Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA	$7.65 million	N/A	N/A	N/A	N/A
Benitec Biopharma	N/A	N/A	-$37.92 million	($1.14)	-11.96

XOMA has higher revenue and earnings than Benitec Biopharma.

Profitability

This table compares XOMA and Benitec Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XOMA	N/A	N/A	N/A
Benitec Biopharma	N/A	-34.82%	-34.11%

Analyst Recommendations

This is a breakdown of current ratings and target prices for XOMA and Benitec Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA	0	0	0	0	0.00
Benitec Biopharma	1	2	7	0	2.60

Benitec Biopharma has a consensus target price of $24.80, indicating a potential upside of 81.95%. Given Benitec Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than XOMA.

Summary

Benitec Biopharma beats XOMA on 5 of the 8 factors compared between the two stocks.

About XOMA

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

About Benitec Biopharma

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.